Why InterCure Ltd.’s (INCR) Stock Is Down 7.10%
As of Friday, July 17, InterCure Ltd.’s INCR share price has dipped by 7.10%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Commentary & Analysis
Why InterCure Ltd.’s (INCR) Stock Is Up 5.26%
As of Tuesday, July 14, InterCure Ltd.’s INCR share price has surged by 5.26%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why InterCure Ltd.’s (INCR) Stock Is Down 11.01%
As of Monday, July 06, InterCure Ltd.’s INCR share price has dipped by 11.01%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why InterCure Ltd.’s (INCR) Stock Is Up 6.91%
As of Tuesday, June 30, InterCure Ltd.’s INCR share price has surged by 6.91%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why InterCure Ltd.’s (INCR) Stock Is Up 7.01%
As of Thursday, June 25, InterCure Ltd.’s INCR share price has surged by 7.01%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | INCR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $56.2 | $579.1 | 17% |
|
| Shares Out (Mil) | 15.9 | 43.0 | 27% |
|
| Institutional Ownership | 11.6% | 84.3% | 8% |
|
| Float (Mil) | 38.0 | 46.8 | 41% |
|
| Beta | 0.35 | 0.62 | 20% |
|
| Avg Daily Volume (000s) | 17 | 285 | 20% |
|
| Price Change (52-week) |
(34.1%) | 63.8% | 22% |
|
| Growth | INCR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 33.2% | 6.7% | 91% |
|
| Net Income (5yr) | 0.7% | (1.4%) | 40% |
|
| EPS (5yr) | 14.5% | 14.9% | 54 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (27.8%) | (14.9%) | 22% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | INCR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $85 | $272 | 25% |
|
| Net Income (TTM) (Mil) | ($11) | ($11) | 28% |
|
| EPS (TTM) | ($0.208) | ($0.500) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | $5 | ($6) | 36% |
|
| Net Cash Flow (TTM) (Mil) | ($9) | $4 | 31% |
|
| Long-Term Debt (Q1) (Mil) | $25 | $7 | 34% |
|
| Enterprise Value (Q1) (Mil) | $104 | $522 | 21% |
|
| Valuation | INCR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.42 | 2.73 | 7% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | INCR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 15.1% | 65.9% | 14% |
|
| Net Margin | (13.2%) | 0.7% | 19% |
|
| ROA | (5.3%) | (24.6%) | 30% |
|
| ROE | (9.6%) | (19.7%) | 28% |
|
| Liabilities to Assets | 42.6% | 35.5% | 33% |
|
| F-Score | 5 | 3 | 51% |
|
InterCure Ltd. did not pass any screens on 7/31/2026.
